{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:01:34Z","timestamp":1787997694624,"version":"build-2784847793"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T00:00:00Z","timestamp":1267488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Numerous studies have reported on the immunophenotype of plasma cells (PCs) in monoclonal gammopathy of undetermined significance (MGUS) and in plasma cell myeloma (PCM), but very few have examined the immunophenotype of normal PCs. In this study, an objective definition of normal range of expression for each antigen was found on normal control PCs. Using these new ranges of normal expression (new method) is different from using a static 20% of PCs cut\u2010off for all antigens as described in the literature (traditional method). These newly calculated normal ranges for each antigen were applied to our data, and compared to histologic and immunohistochemical findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Bone marrow samples from 46 patients with PC neoplasms and 15 normal controls were studied. A minimum of 100 PC were analyzed for each patient and control sample. An 8\u2010color staining method was applied to study the immunophenotype of PCs, using a BD FACSCanto II.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>By the new ranges of normality calculated in this study it was determined that different antigens have different level of expression on polyclonal PCs. CD19 correlated with histology by both the traditional and new methods, but had superior correlation by the new method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>This report is the first 8\u2010color immunophenotypic study of PCM in which a \u201crange of normal expression\u201d for each antigen is defined. This is a critical step to help distinguish between a normal and neoplastic PC immunophenotype and discern which antigens are of diagnostic importance. \u00a9 2010 Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.20517","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T16:45:52Z","timestamp":1267548352000},"page":"231-238","source":"Crossref","is-referenced-by-count":56,"title":["Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology"],"prefix":"10.1002","volume":"78B","author":[{"given":"Elisa","family":"Cannizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bellio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah R.","family":"Sohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janessa J.","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Preffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-149-9"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_5_4_2","first-page":"706","article-title":"CD221 (IGF\u20101R) is aberrantly expressed in multiple myeloma, in relation to disease severity","volume":"90","author":"Bataille R","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029355"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4700"},{"key":"e_1_2_5_7_2","first-page":"547","article-title":"Patients with CD45 negative multiple myeloma receiving high\u2010dose therapy have a shorter survival than those with CD45 positive multiple myeloma","volume":"89","author":"Moreau P","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_8_2","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau M","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.72653.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.9.1739.1739"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.039"},{"key":"e_1_2_5_13_2","first-page":"837","article-title":"Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells","volume":"86","author":"Sezer O","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4120"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705857"},{"key":"e_1_2_5_16_2","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \u201cmany and multiple myelomas\u201d and of new targets for myeloma therapy","volume":"91","author":"Bataille R","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3333"},{"key":"e_1_2_5_18_2","first-page":"1293","article-title":"[Close correlations between CD20 expression, a small mature plasma cell morphology and t(11; 14) in multiple myeloma]","volume":"46","author":"Matsuda I","year":"2005","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_5_19_2","first-page":"715","article-title":"Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An eastern cooperative oncology group study","volume":"62","author":"Fonseca R","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1489"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2000.0342"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07975.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701813018"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609052429"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040198"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-003-0934-8"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07024.x"},{"issue":"12","key":"e_1_2_5_28_2","first-page":"17","article-title":"Sliwkowski MX CD20: A gene in search of a function","volume":"27","author":"Riley JK","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00027-4"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.3.1032"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000101557"},{"key":"e_1_2_5_32_2","first-page":"297","article-title":"Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules","volume":"6","author":"Pilarski LM","year":"1992","journal-title":"Hematol Oncol Clin North Am"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80259-8"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200201000-00008"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404558"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500467784"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500271269"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1309\/5EL22BH45PHUPM8P"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190412331283279"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20443"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20799"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404815"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0297"},{"key":"e_1_2_5_47_2","first-page":"202","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"McKenna RW"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03513.x"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2004.01834.x"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62556-4"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401211"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.20517","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.20517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:45:43Z","timestamp":1697445943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.20517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,2]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1002\/cyto.b.20517"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.20517","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,2]]}}}